Research progress of small interfering RNA delivery system and chemical modification
In 2018,the U.S.FDA approved the first small interfering RNA(siRNA)drug Patisiran,marking a brand-new era for RNA interference therapy.siRNA has developed rapidly in recent years due to its unique drug-forming advantages.Five siRNA drugs have been approved for marketing by the FDA.However,there are still many problems in targeting and efficacy in therapeutic applications.In order to develop new products with more potential value,it is necessary to deeply explore the current status of siRNA drug discovery and development.This article reviewed the advantages and hindrances of siRNA in drug discovery,focused on the research progress of chemical modification strategies and delivery systems of siRNA drugs,in order to provide a reference for the subsequent research.
small interfering RNARNA interferencedelivery systemchemical modification
NETL
NSTL
万方数据
